Kailera Therapeutics, Inc. (KLRA)

NASDAQ: KLRA · Real-Time Price · USD

17.56

-0.76 (-4.15%)

Aug 20, 2026, 3:30 PM EDT - Market open

Kailera Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Selling, General & Admin	61.87	49.23	14.06
Research & Development	251.4	109.11	10.46
Operating Expenses	313.27	158.34	24.52
Operating Income	-313.27	-158.34	-24.52
Interest & Investment Income	22.96	11.05	3.76
Other Non Operating Income (Expenses)	-1.89	-1.66	12.29
EBT Excluding Unusual Items	-292.2	-148.96	-8.46
Pretax Income	-292.2	-148.96	-329.57
Net Income	-292.2	-148.96	-329.57
Net Income to Common	-292.2	-148.96	-329.57
Net Income Growth	-	-	-
Shares Outstanding (Basic)	130	0	-
Shares Outstanding (Diluted)	130	0	-
Shares Change	-	-	-
EPS (Basic)	-2.25	-7819.98	-
EPS (Diluted)	-2.25	-7819.98	-
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-223.7	-122.3	-185.35
Free Cash Flow Per Share	-1.73	-6420.52	-
EBITDA	-312.88	-158.03	-24.44
D&A For EBITDA	0.39	0.31	0.08
EBIT	-313.27	-158.34	-24.52

SEC Filings: 10-K · 10-Q